JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding BRSR FY 26''.
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
JB Chemicals & Pharmaceuticals has submitted its BRSR for FY 2025-26 in compliance with SEBI Listing Regulations. The company operates 8 manufacturing plants in India and serves 28 states domestically and 40+ countries internationally, with exports accounting for 35% of total turnover. The report shows 5,324 permanent employees with 10.37% women representation, and 8 board members including 1 woman director. Environmentally, the company achieved 43%+ renewable energy usage (up from 37%), reduced Scope 1 emissions by over 7%, and maintains Zero Liquid Discharge at all sites. The report is assured by DNV Business Assurance India. Leadership transitioned with Aman Mehta appointed as Managing Director (w.e.f. January 21, 2026) succeeding Nikhil Chopra.
The BRSR filing demonstrates JB Pharma's growing focus on ESG metrics with notable progress on renewable energy and emissions reduction. The company's commitment to carbon neutrality by FY 2032-33 and water positivity targets indicate long-term sustainability planning, which could positively influence ESG-focused investors. The leadership transition and governance disclosures show stable corporate governance.